– USA, NY – Viramal, an emerging specialty pharmaceutical company developing therapeutics that improve the quality of women’s health, today announced the appointment of William Bologna as Chairman of the Board of Directors, effective immediately. Mr. Bologna is also the Company’s chief scientist.
Bill Bologna is a pioneer in women’s healthcare who has successfully developed and licensed market-leading products in fertility and female sexual health. He co-founded Nasdaq listed Columbia Laboratories (now Juniper Pharmaceuticals) in 1986, one of the first publicly traded women’s health companies in the United States. Under his tenure, the company commercialized Crinone®, Replens®, RepHresh®, Striant®, Advantage-S and other well-known products, a number of which have regulatory approval to be sold in over 90 countries.
During his career, Mr. Bologna has been granted more than 50 patents covering new drug delivery systems, unique pharmaceutical compositions and methods for treating female health disorders, with another eight patents pending. Mr. Bologna’s patents cover women’s health disorders such as endometriosis, infertility, premature labor, dysmenorrhea, and vaginal infections, among other conditions.
“Bill Bologna is a leader in female healthcare and we are thrilled to welcome him to Viramal as our Chairman. Bill has a successful track record of developing and commercializing novel therapies that improve the quality of women’s health,” said Oliver Bates, Viramal’s Chief Executive Officer. “His highly relevant experience directly aligns with Viramal’s strategy to produce a step change in existing female healthcare products, as well as develop innovative products that target unmet therapeutic areas, by leveraging our unique platform delivery technologies.”
“Viramal has a highly differentiated portfolio of products that should significantly improve the standard of care available to women and I am excited to capitalize on this opportunity,” said Mr. Bologna. “Our treatments, which span fertility, menopausal hormone therapy, contraception and sexual health, overcome significant side effects prevalent in existing products in what have traditionally been underserved markets. I look forward to working with the Board of Directors and management team to advance Viramal’s unique product portfolio. We expect to launch the majority of our products within the next several years and capture significant commercial opportunities both in the Unites States and worldwide.”
Prior to working at Juniper Pharmaceuticals, in 1980 Mr. Bologna founded one of the first medical consulting, marketing and advertising companies in the United States, Bologna International, which provided services to multinational pharmaceutical companies. In addition, Mr. Bologna has held senior management positions in international medical consulting and publishing companies.
He holds an MBA degree and a Bachelor of Science in Pharmacy from Fordham University.
Viramal is an emerging specialty pharmaceutical company focused on the development of therapeutics that improve the quality of women’s health. The Company’s well-recognized management team has pioneered market-leading products in fertility and female sexual health, having successfully developed and licensed Crinone®, Replens® and RepHresh®. Viramal produces a step change in these existing products, as well as develops innovative products that target unmet therapeutic areas, by leveraging novel platform delivery technologies that offer greater safety, efficacy and patient acceptability with far fewer side effects. The Company’s robust women’s health clinical development pipeline includes treatments for fertility, menopausal hormone therapy, contraception and sexual health. In addition, Viramal’s only male product, TestoCream (transdermal delivery of testosterone), has shown 81% success in a partially completed Phase III study.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.